STOCK TITAN

Talis Biomedical to Announce First Quarter 2021 Financial Results on May 11, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the first quarter after market close on Tuesday, May 11, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.

Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 7657867. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.

About Talis Biomedical
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio.

Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407


Talis Biomedical Corporation

NASDAQ:TLIS

TLIS Rankings

TLIS Latest News

TLIS Stock Data

15.89M
1.01M
8.31%
43.93%
0.73%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About TLIS

high complexity diagnostics at the point-of-need. bridging the gap between discovery and delivery at slipchip we integrate high-complexity laboratory assays, into an easy to perform, affordable and accessible sample-to-answer format across a wide range of environments. what if physicians could make rapid, individualized optimal treatment decisions? today, patients are often forced to endure days of waiting for lab results. as a result, doctors initially treat everyone with a strong cocktail of drugs. this approach is costly and can be harmful to patients.it also leads to serious drug resistance problems. our technology will allow doctors to provide optimal therapies to patients sooner. empowering physicians to make informed treatment decisions quickly. minimizing risks and reducing patient recovery times.